ثنائي وضع الخيار: الفوركس قائمة الخيارات الثنائية

In Preparation for the R&D Update

I copied here for convenience, the PR of 11/22/22:

"CytoDyn to Host R&D Update on Wednesday, December 7, 2022

VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it will host a virtual R&D Update on Wednesday, December 7, 2022, beginning at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time.
During this event, Company management and members of its Scientific Advisory Board will provide an overview and update on the Company's R&D and clinical development strategy and activities.
CytoDyn's R&D Update will include the following:
Access to the event will be available at the Company's website in the "Investors" section. A replay will be archived on the Company's website following the live presentation.
Virtual R&D Update Webcast Access Information
Date:Wednesday, December 7, 2022Time:11:00 a.m. Eastern Time / 8:00 a.m. Pacific TimeAccess:https://event.choruscall.com/mediaframe/webcast.html?webcastid=jrd4LizJ
The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until January 7, 2023."
---
In previous posts, I've stated something to the effect, "Cyrus is introducing his right rear rampart...". That, in part, was referencing this post:
https://www.reddit.com/LeronLimab_Times/comments/y3bfrq/chess_played_by_a_master_all_the_kings_horses_and/?utm_source=share&utm_medium=web2x&context=3
​
But, from that post, I was referencing this section specifically:
"So with what I have explained above about the clinical hold and the Investigational Brochure, the ISS & ISE as well as the massive imbalance of the Short Cabal armed by millions of shares held by hedge funds vs. the Retail share holders who buy and sell just a few thousand of shares at a time without a central controller, and with the looming outcome of the Amarex arbitration, does Cyrus have any choice but NOT to compromise? How do you think Cyrus feels with these big walls surrounding him on every side? Every day, with no way out, something new presents itself orchestrated by Big Pharma, that he has to contend with. Faithfully, unceasingly, working forthright and diligent, righting the wrongs, facing the situation, the obstacles, one by one, day by day, to the point now, where they have become scared of him, because they thought they were undefeatable, their stronghold, unsinkable. Little do they know, they built the Titanic. CytoDyn has benefited greatly in bringing Cyrus to the forefront. He has shown himself able to tackle the millions with the thousands, able to flick the switch upon their attack, to blunt it and to confuse it. Behind closed doors, he strategizes and designs the attack, or the confusion, because he has the upper hand, he owns the work, he possess the two edged sword and dissects the way in towards the means to their merciless defeat, the road, unto a definitive and assured CytoDyn spoil.
So the next move is? As to my question, where are we? So as determined essentially by Amarex, and thanks to CytoDyn's prior leadership, HIV has been laid aside for another day. Covid has been hammered. But Cyrus found a way to get that Investigational Brochure submitted which means that CytoDyn was successful in aggregating all the safety and efficacy data across all Amarex trials and that was surely validated by the external audit enforcer as well, otherwise, Cyrus would not have submitted the IB. So the IB passed the test of the external auditor. Like Scott Kelly said, "We have the data."
Since NASH and Oncology did not have sufficient clinical trials to produce safety and efficacy data, these indications have been left alone and therefore, these indications come to the forefront. Now, Cyrus strikes where he won't be hurt. He has the data on NASH and Oncology. There is more to NASH than we know and there is more to Oncology than we know. Think Mazen Noureddin and EASL from June, 2022 and MD Anderson and Naoto Ueno, Jangsoon Lee, Ph. D from 1 year ago and having 21 peer-reviewed publications of which 18 of them have Dr. Naoto Ueno name as well. But Cyrus knows
The Game
He who plays the game: Cyrus, being a chess player, has got his rear flank arranged.
Two Rooks, two Knights, two Bishops, one Queen and one King.
I'm not sure how Cyrus plays, but I think at least for the time being, he has all the players for the game at hand, and he will re-arrange or arrange a new as the game changes as he sees fit. Here is a possible scenario for the game today. But remember, it is his game and his technique. He can play it the only way he knows is to win.
Right Rook: Mazen Noureddin, NASH, Mechanisms and Biomarkers;
Left Rook: Jordan Lake, HIV, NIH;
Right Knight: Hope Rugo, Breast Cancer who is widely published; Stefan Gluck, Celgene and Naoto Ueno, MD Anderson, Oncology;
Left Knight: Kabir Mody, GI Oncology, Liver, Pancreas and Eric Mininberg, Oncology and Hematology and Oncology;
Right Bishop: Jonah Sacha, HIV Prep and HIV Cure:
Left Bishop: Otto Yang, Covid 19, Long Haulers, Immunology;
Queen: Jay Lalezari, Principle Investigator; Scott Kelly, Chief Medical Officer & Chief Science Officer and Chris Recknor, Principle Investigator; (I don't believe Chris Recknor is any longer a part of the rear flank, and probably is not even a part of CytoDyn, but this is not the point of this post, so I won't elaborate);
Today, I would replace Chris Recknor with the VP of Operations Bernie Cunningham and Senior Director of Clinical Operations, Joseph Meidling.
I would also like to add to the Queen, Stephen M. Simes Director and Ryan Dunlap Director. Cyrus recently said on 10/31/22 Webcast, "8:25: As you know, we recently strengthened our board, with the addition of Stephen Simes, who has extensive expertise in the operating of public bio-technology companies as both the CEO and as a board member. As well as the addition of Ryan Dunlap, who brings deep knowledge in the financial and audit matters and has experience in navigating the many of the challenges that CytoDyn is having. These additions, along with continued corporate re-structuring, and a focused development strategy, are part of our transformation into a more effective, and efficient biotechnology company, with meaningful opportunity to bring innovative therapy to difficult to treat diseases."
King: Antonio Migliarese, who deals with Big Money, Tanya Urbach who deals with Big Media;
These men and women make up Cyrus' rear flank and they are his means of dealing with the entrapment that CytoDyn finds itself in. No, Cyrus is not silent, though he speaks little, nor is he still or inactive, though he boasts not. There are many pawns in the game who also serve him and perform his will, who moves the pieces and plays the game.
Next move Cyrus..."
---
Somehow, I had placed these 3 individuals on Cyrus' right side. Cyrus introduces right rear rampart 2 days prior to the 2022 Annual Share holders Meeting. We know that for CytoDyn to survive, clinical trials for Leronlimab must take place. We know that trials must resume very soon.
In the 9/28/22 Conference Call, Cyrus stated, "17:50: So the near term financing requirements for the company will be focused on re-entering clinical trials for NASH as expeditiously as possible. Now while we do plan to continue development in oncology, our focus will be toward certain solid tumors to insure that we can collect sufficient data in enough patients within select indications, namely, colorectal cancer, breast cancer and potentially in non-small cell lung cancer with combination agents. We said colorectal cancer or CRC, we will be looking at the metastatic, microsatellite stable population. This represents about 85% of all the diagnosed cases of CRC. This particular segment of CRC hasn't seen any meaningful therapeutic advancement in nearly a decade. Yet, the Survival rates in that population have considerable room for improvement. In breast cancer, rather than focus on only the mTNBC population, which really only represents about 15% of the total growth cancer market and has seen increased competition advancements in check point inhibitors and antibody drug conjugates, we are going expand our focus into Hormone receptor positive, HER2 negative population which stands for roughly about 70% of the total market. We believe that mCRC and mTNBC each represent large opportunity for leronlimab, and we believe that the mechanistic rationale for using the drug in those populations is quite strong for a CCR5 inhibitor. Let me be clear, that we intend to run these cancer studies over sufficient period of time to generate a robust and meaningful clinical data set that a potential partner would find compelling."
In the 10/31/22 Webcast, Cyrus stated, "7:34: We continue to view these indications as excellent opportunities to maximize shareholder value. We remain committed to the continued development of Leronlimab in these indications and look forward to Re-Starting Trials soon. In addition, we are fully committed to the best possible management of future trials possible, including Timely Monitoring and Data Integrity."
9:24: Now, regarding our NASH program, which we are particularly excited about, the clinical signals generated in our Exploratory Phase II CDI NASH 01 Trial, included surrogate imaging at points for both hepatic fat fraction and fibro-inflammatory activity. The results from that trial allowed us to identify appropriate dosing strategy for our next NASH trial. And demonstrating potential anti-fibrotic activity is an exciting outcome that we plan to study in future trials with correlated liver biopsies in a larger sample of patients. We will be providing an update on our NASH clinical program in the next investor call.
10:00: Regarding Oncology, as we discussed in our last quarterly call, we plan to focus on Colo-Rectal and Breast Cancer, where we already have a Fast Track Designation for mTNBC. Our Pooled Data in the Relapsed Refractory TNBC population showed promising survival data that we plan to follow up on. I want to re-iterate that NASH and solid tumors, each represent multi billion dollar valuation opportunities for the company, and we believe that Leronlimab has the potential to become the standard of care in these indications in the future."
---
Knowing that trials must resume very soon, in the upcoming meetings this week, we should be able to glean the means by which these trials become actualized. Some of us believe that Partnership will be that means; some of us believe that a Buy Out will be the way and some of us believe that we will do it all on our own. Taking the words of Cyrus above at face value, it is clear that a Buy Out is not being planned for, although, I don't believe neither he, nor the board nor the shareholders would turn down a reasonable offer. Certainly, Cyrus is focusing on the indications of NASH, Oncology and HIV and is also focused on getting Leronlimab approved for those indications. He is not setting the company up for Buy Out. So the toss up in discussion below, is between Partnership and doing it alone.
From these words, "Let me be clear, that we intend to run these cancer studies over sufficient period of time to generate a robust and meaningful clinical data set that a potential partner would find compelling.", one might infer that Cyrus has a plan for doing it alone, allowing Leronlimab to do the work in providing the data that a Partner would step in.
However, on Wednesday, Cyrus introduces his right rear rampart and they may have something else in store, that we may consider. They may have information coming from other companies they are directly familiar with who are also in NASH, Oncology and HIV, who are interested in and looking at Leronlimab and are considering or are already in talks of Partnership. In this discussion, I will set forth some reasons why I feel the strongest potential CytoDyn has in Partnership is First in Oncology, then, Secondly in HIV, and lastly, Thirdly in NASH.
---
FIRST
Oncology is broad, but Cyrus aims to pursue metastatic Breast Cancer and metastatic Colon Cancer and Primary Solid Tumors and possibly Non Small Cell Lung Cancer, as he stated on 9/28/22 Conference Call written above.
To pursue cancer, Cyrus plans on using Combination Agents as stated above. A combination Agent that would not need a partner would be chemotherapy. This is an option, but I don't think Cyrus will trial Leronlimab with chemotherapy given the stark contrast in side effect profiles between the two drugs, Leronlimab and chemotherapy, I mean, it makes little sense. Then what Combination Agent would be considered? If a non-chemotherapy Combination Agent were used, it would be done with a Partner, especially, if that Combination Agent was say a check point inhibitor, like a PD-1 or PD-L1 inhibitor or blockade. Leronlimab is especially advantageous in extinguishing the metastasis generated by primary tumors and some check point inhibitors are quite useful at the obliteration of the main tumor, as is Leronlimab. Take the GSK PD-1 blocker dostarlimab which was shown to obliterate colon cancer in 14/14 individuals.
Speaking on Oncology will be Dr. Gluck who worked with Celgene and Regeneron. Celgene merged with Bristol Myers Squibb in 2019. BMS has Opdivo or nivolumab is a monoclonal antibody like Leronlimab, but it is a PD-1 inhibitor, like GSK's dostarlimab. Regeneron has Cemiplimab which is also a monoclonal antibody and is also a PD-1 inhibitor.
So if Oncology trials are to be performed with a partner, then, Cyrus' statement, "Let me be clear, that we intend to run these cancer studies over sufficient period of time to generate a robust and meaningful clinical data set that a potential partner would find compelling." makes me think, that this trial may be conducted with another type of partner. Not so much a Big Pharma partner, but rather a Partner with the funding necessary to carry it out, but not for the purpose of selling their drug, but for the benefits derived from selling the combination product.
Remember MD Anderson? They researched how Leronlimab performed in mTNBC with a PD-1 inhibitor. We still await those results. Surely, the results will be exciting to see and should provide a stimulus, but with what check point inhibitor were the MD Anderson research tests conducted? Could this be the reason we are not yet aware of the results of that research? If that information was published, then that would have revealed the Partner, right? But that would make it a Big Pharma Partner? Not necessarily. Could have been a small company's check point inhibitor, for instance, Coherus in California, has a PD-1 inhibitor named Toripalimab which could have been tested and found to work perfectly well in concert with Leronlimab against the broad spectrum of Breast Cancer which are CCR5 dependent.
​
SECOND
Why do I place HIV second? First off, everybody knows that Leronlimab completely obliterates HIV. It has met clinical significance in Multi Drug Resistant, but we know, but can't advertise that it is the same in -mono and first line, but we can't say that ...yet. The - MDR indication has been sacrificed and a partnership will not be forthcoming on MDR. That is a given. We know that Jonah Sacha is working on important research on an HIV Functional Cure, on an HIV Adult Prep, and on an HIV Prep Mother to Child. Dr. Sacha should discuss this, but pre-clinical results won't be available until 2025 or so it has been written. Therefore, the partnerships that result from these HIV indications are definitely in the future. However, a partnership for HIV that may result in the nearer term may have more to do with NASH, than it has to do with HIV.
There is a strong correlation between patients who get HIV also seem to develop NASH. Taken from 6/30/22 Conference Call, Chris Recknor spoke, "There are genetic differences in CCR5 that have been studied as related to the risk for HIV and HIV progression and some CCR5 haplotypes over produced CCR5 thus increasing the risk for HIV b/c there is more CCR5 that the virus can use to enter. Since these patients have increased CCR5, from these HIV studies, we have hypothesized that they may need more LRM in the NASH study. The exploratory analysis showed a 28% reduction in MRI PDFF fat, with corresponding reduction in MRI cT1 fibro-inflammation for patients with over expressed CCR5 haplotypes, when treated with 700 mg of LRM. and the number of patients were small, (5) representing only 23% of those in the 700mg group, but we noticed key distinct changes in biomarkers for this haplotype group, perhaps suggestive that these CCR5 haplotype patients may have a different etiology for NASH. But further exploratory studies need to be performed.
LRM binding to CCR5 is thought to be essentially associated with alterations in CCL5 or RANTES and then NASH in this exploratory biomarker analysis, showed that LRM reduces CCL5, and other chemokines CCL2, 3, 11 and 18. These chemokines act as a beacon to attract other cells in the area. The difference is really big because we thought we just worked on CCR5, but we are also working on CCL2, 3, 11 and 18. In NASH studies, we can see correlation b/w CCL3 which is Macrophage Inflammatory Protein Alpha 1 levels and they increase in severity of NASH on biopsies. So patients in full blown NASH, show highest levels of CCL3, but LRM reduced CCL3 with 350mg compared to placebo from baseline from week 14. CCL2 is another one that moves monocytes, called Monocyte Chem-Attratic Protein and is a key biomarker associated with NASH. LRM reduced mean CCL2 from baseline to week 14 in 350mg group compared to placebo.
Now when dr. Chung was talking about HIV and NASH, this has great application, because CCL2 applied to the treatment of the HIV patients is important because lower CCL2 levels correlate with less viral replication in effect to macrophages, less rapid feeding, of the latent HIV reservoir and less chance HIV central nervous system invasion. The ability to reduce CCL2 may have application to HIV and NASH and may really position LRM very effectively now to outpatients.
This last Bolded sentence was the most important line which Chris Recknor said when it comes to the relationship between HIV and NASH and that is why I place HIV second for the possibility of Partnership.
​
THIRD
The reason why I think NASH (by itself), is last for likelihood of partnership, is because from the EASL conference, our data was strongest in fibrolytic capacity of Leronlimab and it performed not as well in the removal of steatosis or fat. So Leronlimab was better at removing scar tissue, (the hard part), than it was at removing fat, but steatosis is very common and although reduced, persists to some degree. Secondly, there aren't any approved drugs for NASH to partner with, (nothing has been successful in removing the scar tissue, except for Leronlimab, which makes it a perfect combination candidate, if there were in fact, a drug that removes steatosis well). Third, our trial only had 70 patients, which were not so many, not so convincing a number for a potential partner. Fourth, But, the trial was very strongly biased towards those who were haplotype matched for CCR5. These patients, in fact, responded very well to Leronlimab for both the removal of fibrous tissue and the removal of steatosis. Therefore, it is possible that we get NASH partnership sooner, but, I think, less likely than for Oncology and less likely than for HIV. Cyrus stated, "The results from that trial allowed us to identify appropriate dosing strategy for our next NASH trial. And demonstrating potential anti-fibrotic activity is an exciting outcome that we plan to study in future trials with correlated liver biopsies in a larger sample of patients." Mazen Noureddin illuminates us on Wednesday and may discuss some potential partners in this space.
​
In Closing
In the 6/30/22 Conference Call, Scott Kelly stated, "32:20 Dr. Scott Kelly: Yes, Chris left with a perfect thing about VCAM b/c we do believe VCAM is important for oncology in LRM. What we are doing now, we are currently evaluating opportunities KOM Smithing ford, in mTNBC program for LRM in combo with a current SOC as well as colon cancer trial, we have animal and human data for mTNBC as well as animal data on the effects of LRM on colon cancer.
We are very encouraged by the exploratory biomarkers data from NASH at the 350mg dose as many of the biomarkers that LRM appeared to effect in NASH are important for oncology program and this exploratory data may inform future trials in oncology." ... " Partnerships, we will continue to pursue partnerships both internationally and domestically for Pharma companies, Academic Institutions, and government funding. We are doing this across multiple indication and we will announce any progress to investors when appropriate." ... "36:07 Scott Kelly: Sure, I'll take the positive news on the Science 1st. We are very encouraged by the fact of LRM on the biomarkers and NASH. Many of these same biomarkers are supported by the literature to be important in our oncology program including CCL2, CCL5, CCL18, VCAM and VEGF. Some of these biomarkers also correlate with the potential to decrease metastasis, control the tumor microenvironment and correlate with antifibrosis and NASH. ...
36:54 Christine: Next question: Why isn't the company publicizing presentations and studies? Has NASH data attracted partnership? Has Amarex issue permanently damaged the BLA applications?
37:10 Scott Kelly: OK, so we certainly acknowledge being more metered and conservative in our publicity. We will be announcing important presentations and studies on a going forward basis. Regarding the NASH, about how NASH attracted partnerships, we just presented the PDFF and cT1 and biomarker data at EASL in London, just to shed some color on the importance of the EASL meeting, there were over 7,000 delegates present or online from 114 countries. There were 1,722 abstracts presented. There were only 4 poster presentations selected for a walking tour with the chairman at EASL. And We were one of those 4. I was present and I can tell you, it was well received by the scientific community. We can not comment on potential partnerships. But there are multiple opportunities for NASH and NASH HIV."
"48:15 Scott Kelly: I want to thank you all for your time this afternoon. We believe we've made significant progress on many fronts. Including search for CEO/President. Progress of LRM. A lot of people asking questions regarding pursuing multiple opportunities for LRM. I want people to understand our thinking behind this. I'll use 2 examples. If you look at Humira, it stands for human monoclonal antibody in rheumatoid arthritis. It is one of the best selling drugs of all time. What Abby did which was so brilliant, was they took the target, TNF, tumor necrosis factor, and that target is important across multiple indications. They have 14 global and 10 US approved indications, and we are trying to do exactly the same thing. It is a very cost effective way to do drug development. Our target is the CCR5 receptor. If one looks at the literature, you will find that it has been implicated in many different indications, including HIV, NASH and oncology. So we will be actively pursuing partnerships to realize the true potential of LRM in these indications. Thank you again for your time."
submitted by MGK_2 to LeronLimab_Times [link] [comments]

$GSTC Globestar Therapeutics (Multiple Sclerosis Biotech Clinical Trials)

$GSTC Globestar History
What is Globestar Therapeutics?
Formerly known as Angiosoma ($SOAN), formerly run by Alex Blankenship. In April 2020, Alex Blankenship was able to secure U.S. patent 10,610,592, a patent developed by Fabrizio De Silvestri (company is 7 to Stand, Inc) from Terni, Italy. https://www.otcmarkets.com/filing/html?id=14747280&guid=xsG-kKvkPiDadth
In December 2020, Blankenship sought a firm that had history with bringing drugs to market, and in March 3, 2021, the board appoints Jim Katzaroff as CEO of both the subsidiary company (Somaceuticals), and parent company (Angiosoma). https://www.otcmarkets.com/filing/html?id=14777626&guid=xsG-kKvkPiDadth.
In August/September Angiosoma changed to Globestar Therapeutics, Inc. Globestar is a clinical stage pharmaceutical company testing a worldwide patented formulation of 3 drugs previously approved by the FDA. Pre-clinical trials in Italy showed the drug combination was effective in the reduction of MS co-morbidities. GlobeStar is initiating discussions with the FDA on clinical trial design in the U.S. in preparation for FDA submission and approval. https://www.otcmarkets.com/stock/GSTC/profile
What is patent 10,610,592 therapy?
The patent specified a combinational tri-drug therapy that harnesses:
  1. Minocycline - An oral tetracycline antibiotic. It's used to treat bacterial infections including respiratory and urinary tract infections.
  2. Fluconazole - An triazole antifungal. Used to prevent and treat a variety of fungal and yeast infections by stopping the growth of CERTAIN types of fungus (candida albicans).
  3. Atorvastatin - A statin HMG CoA reductase inhibitor. Commonly used to lower blood levels of LDL cholesterol, increase levels of HDL cholesterol and to lower triglycerides. It's also an effective immunomodulatory agent shown to prevent autoimmune encephalomyelitis in animal model studies. https://www.otcmarkets.com/filing/html?id=15232865&guid=xsG-kKvkPiDadth
Multiple Sclerosis affects roughly 2,300,000 million people a year costing roughly $70,000 yearly. This therapy would dramatically drop costs.
Who is on the Globestar Therapeutics, Inc team?
[Suppressed Image]
Bill Farley - https://www.otcmarkets.com/filing/html?id=14875624&guid=xsG-kKvkPiDadth Brooke Greenwald - https://www.otcmarkets.com/filing/html?id=14933181&guid=xsG-kKvkPiDadth Steven F. Penderghast David Croom Dr. Leonard Wisneski, MD, FACP
Subsequently, Kenin Spivak was also brought in as a consultant in April 2022 (https://www.imdb.com/name/nm1221859/bio). https://www.otcmarkets.com/filing/html?id=15725607&guid=xsG-kKvkPiDadth
Was there an initial clinical study?
Yes. The initial study consisted of 150 volunteers, 90 subjects ages (25-65) with MS between 5-20 years (including 60 control volunteers). They used Barthel Index (used as a mobility disability index). They also used a scale for muscle imbalance (Kendall Scale), before and after treatment.
The subjects received 2 doses/day for 45 days, along with a controlled diet.
[Suppressed Image]
[Suppressed Image]
Fabrizio de Silvestri (https://patents.justia.com/inventofabrizio-de-silvestri) is a lawyer by trade (1998), but suffers, himself, from Multiple Sclerosis. In 2005, he started studying forensic medicine. He researched to try to find a better therapy filing the patent in 2015 (Applied in 2014). In regard to speaking about the therapy itself, he said,
My patented formula is a composition for treating neurodegeneration, including an antibiotic, an antifungal agent, and a lipophilic potentiating agent in synergistically effective amounts.
Has the team developed North American/World Projections?
[Suppressed Image]
[Suppressed Image]
Has James Katzaroff tried approaching hospitals?
In October 4, 2021, Leonard Wisnecki, MD met with Merit Cudkowitz, M.D., Chief of Neurology, Mass General Hospital, on July 19, 2021. This fell through but he had talks with numerous other hospital including Cedar Sinai, Stanford, and numerous others that allude me.
Since then, we have been waiting patiently for Jim to make the magic happen. They secured financing with New York Bay Capital which was in the tune of $19-21,000,000 from anecdotal calls with Jim. Which one would expect with clinical trials.
In April/May, Jim appeared on the Emerging Growth Conference to provide some updates to the shareholders. Not much was provided other than looking for a hospital. In November 10, 2022, Jim updated the shareholders that he was deep in discussions with Apollo Hospitals. An international hospital company with revenues in the billions and a staffing in the 10s of the thousands.
submitted by FlipMovieScript to pennystocks [link] [comments]

Collected 92 jobs from various job boards

Hello friends! These are the open remote positions I've found that were published today. See you tomorrow! Bleep blop 🤖
submitted by remote-enthusiast to remotedaily [link] [comments]

Collected 95 jobs, tech + non-tech

Hello friends! These are the open remote positions I've found that were published today. See you tomorrow! Bleep blop 🤖
submitted by remote-enthusiast to remotedaily [link] [comments]

Bankman-Fried Resigns From FTX, Puts Empire in Bankruptcy - Filings include FTX.com, FTX US and Alameda Research

Sam Bankman-Fried’s digital-asset empire filed for Chapter 11 bankruptcy in Delaware, capping a rapid downfall for the 30-year-old entrepreneur and onetime crypto king.
Bankman-Fried resigned as chief executive officer of the FTX Group as part of the filings, and John J. Ray III was appointed to replace him, the statement said. Ray, a turnaround and restructuring expert, has previously served senior roles in bankruptcies including Enron Corp.
Crypto assets dropped on the news, with Bitcoin slumping as much as 8% before regaining some ground. Ether and smaller tokens also declined. Solana, which was backed by Alameda, tumbled 10%. FTX’s implosion came almost exactly one year after Bitcoin peaked at around $69,000. BlockFi, a troubled crypto lender that received emergency financing from FTX US earlier this year, on Thursday said it will pause client withdrawals citing “a lack of clarity” over the status of Bankman-Fried’s empire.
134 FTX Entities filed for bankruptcy:
  1. Alameda Aus Pty Ltd
  2. Alameda Global Services Ltd.
  3. Alameda Research (Bahamas) Ltd
  4. Alameda Research Holdings Inc.
  5. Alameda Research KK
  6. Alameda Research LLC
  7. Alameda Research Ltd
  8. Alameda Research Pte Ltd
  9. Alameda Research Yankari Ltd
  10. Alameda TR Ltd
  11. Alameda TR Systems S. de R. L.
  12. Allston Way Ltd
  13. Altalix Ltd
  14. Analisya Pte Ltd
  15. Atlantis Technology Ltd.
  16. B for Transfer Egypt
  17. B Payment Services Nigeria
  18. B Transfer Services Ltd
  19. B Transfer Services Ltd. UAE
  20. B Transfer Services Uganda
  21. Bancroft Way Ltd
  22. BitPesa Kenya Ltd.
  23. BitPesa RDC SARL
  24. BitPesa Senegal Ltd.
  25. BitPesa South Africa
  26. BitPesa Tanzania Ltd.
  27. BitPesa Uganda Ltd.
  28. Bitvo, Inc.
  29. Blockfolio Holdings, Inc
  30. Blockfolio, Inc.
  31. Blue Ridge Ltd
  32. BT Payment Services Ghana
  33. BT Payment Services South Africa
  34. BT Payments Uganda
  35. BT Pesa Nigeria Ltd.
  36. BTC Africa S.A.
  37. BTLS Limited Tanzania
  38. Cardinal Ventures Ltd
  39. Cedar Bay Ltd
  40. Cedar Grove Technology Services, Ltd
  41. Clifton Bay Investments LLC
  42. Clifton Bay Investments Ltd
  43. CM-Equity AG
  44. Corner Stone Staffing
  45. Cottonwood Grove Ltd
  46. Cottonwood Technologies Ltd.
  47. Crypto Bahamas LLC
  48. DAAG Trading, DMCC
  49. Deck Technologies Holdings LLC
  50. Deck Technologies Inc.
  51. Deep Creek Ltd
  52. Digital Custody Inc.
  53. Euclid Way Ltd
  54. Exchange 4 Free Seychellen
  55. Exchange 4Free Australia Br.
  56. Exchange 4Free Ltd.
  57. Exchange 4Free South Africa Br.
  58. Exchange 4Free Swiss Branch
  59. Finfax Company
  60. FTX (Gibraltar) Ltd
  61. FTX Canada Inc
  62. FTX Certificates GmbH
  63. FTX Crypto Services Ltd.
  64. FTX Digital Assets LLC
  65. FTX Digital Holdings (Singapore) Pte Ltd
  66. FTX EMEA Ltd.
  67. FTX Equity Record Holdings Ltd
  68. FTX Europe AG
  69. FTX Exchange FZE
  70. FTX Hong Kong Ltd
  71. FTX Japan Holdings K.K.
  72. FTX Japan K.K.
  73. FTX Japan Services KK
  74. FTX Lend Inc.
  75. FTX Marketplace, Inc.
  76. FTX Products (Singapore) Pte Ltd
  77. FTX Property Holdings Ltd
  78. FTX Services Solutions Ltd.
  79. FTX Structured Products AG
  80. FTX Switzerland GmbH
  81. FTX Trading GmbH
  82. FTX Trading Ltd
  83. FTX TURKEY TEKNOLOJİ VE TİCARET ANONİM ŞİRKET
  84. FTX US Derivatives LLC
  85. FTX US Services, Inc.
  86. FTX US Trading, Inc
  87. FTX Vault Trust Company
  88. FTX Ventures Ltd
  89. FTX Ventures Partnership
  90. FTX Zuma Ltd
  91. GG Trading Terminal Ltd
  92. Global Compass Dynamics Ltd.
  93. Good Luck Games, LLC
  94. Goodman Investments Ltd.
  95. Hannam Group Inc
  96. Hawaii Digital Assets Inc.
  97. Hilltop Technology Services LLC
  98. Hive Empire Trading Pty Ltd
  99. Innovatia Ltd
  100. Island Bay Ventures Inc
  101. K-DNA Financial Services Ltd
  102. Killarney Lake Investments Ltd
  103. Ledger Holdings Inc.
  104. LedgerPrime Bitcoin Yield Enhancement Fund, LLC
  105. LedgerPrime Bitcoin Yield Enhancement Master Fund LP
  106. LedgerPrime Digital Asset Opportunities Fund, LLC
  107. LedgerPrime Digital Asset Opportunities Master Fund LP
  108. Ledger Prime LLC
  109. LedgerPrime Ventures, LP
  110. Liquid Financial USA Inc.
  111. LiquidEX LLC
  112. Liquid Securities Singapore Pte Ltd
  113. LT Baskets Ltd.
  114. Maclaurin Investments Ltd.
  115. Mangrove Cay Ltd
  116. North Dimension Inc
  117. North Dimension Ltd
  118. North Wireless Dimension Inc
  119. Paper Bird Inc
  120. Pioneer Street Inc.
  121. Quoine India Pte Ltd
  122. Quoine Pte Ltd
  123. Quoine Vietnam Co. Ltd
  124. SNG INVESTMENTS YATIRIM VE DANIŞMANLIK ANONİM ŞİRKETİ
  125. Strategy Ark Collective Ltd.
  126. Technology Services Bahamas Limited
  127. Tigetwit Ltd
  128. TransferZero
  129. Verdant Canyon Capital LLC
  130. West Innovative Barista Ltd.
  131. West Realm Shires Financial Services Inc.
  132. West Realm Shires Services Inc.
  133. Western Concord Enterprises Ltd.
  134. Zubr Exchange Ltd
submitted by marketGOATS to marketgoats [link] [comments]

List of 94 remote jobs from last couple of days

Hello friends! These are the open remote positions I've found that were published today. See you tomorrow! Bleep blop 🤖
submitted by remote-enthusiast to remotedaily [link] [comments]

Last Week in Collapse: April 2-8, 2022

The new IPCC Report came out, and the UN says it’s now or never. Apparently, we chose never.
This is Last Week in Collapse, a long post I make at the end of every week, curating some of the most important, depressing, surprising, reassuring, demoralizing, helpful, notable, timely, or otherwise must-see events in Collapse.
This is the 15th newsletter. Last week’s newsletter (March 26-April 1) is here if you missed it. Starting this week, you can also find these newsletters on SubStack, or sent to your email inbox (more explained near the bottom).
This third part of the 6th Intergovernmental Panel on Climate Change (IPCC), brought to you by the United Nations, was released on April 4th.
A new IPCC report comes out roughly every 7 years. The latest edition, the 6th, came out in three parts: I. The Physical Science Basis; II. Impacts, Adaptation and Vulnerability; and III. Mitigation of Climate Change. The latest version focuses on preventing the worst possible outcomes.
Such outcomes will not be prevented. The full Climate Mitigation report (which is 2,913 pages long) is too long to read, but the 64-page “Summary for Policymakers” isn’t any more sanguine. Try the “Technical Summary” (drafted in November 2021) if you’re more of a science wonk. For those of you who need a quick summary, here are some highlights.
The report contains such gems like “Warming cannot be limited to 2°C or 1.5°C without rapid and deep reductions in energy system CO2 and GHG emissions… Energy demands and energy sector emissions have continued to rise.” The report includes this mildly hopeful line: “Global GHG emissions are projected to peak between 2020 and at the latest before 2025”—if you believe it. Hard to believe when India’s demand for coal is so high that suppliers can’t find enough coal to alleviate electricity blackouts in parts of the country, and stockpiles are running out.
The IPCC includes some talk on social engineering that seems impossible. “Collective action as part of social or lifestyle movements underpins system change (high confidence). Collective action and social organising are crucial to shift the possibility space of public policy on climate change mitigation.” At least Pinterest is banning climate misinformation now—but what qualifies as misinformation?
If you’re wondering how you can be part of the solution, the IPCC says, “​​Among 60 identified actions that could change individual consumption, individual mobility choices have the largest potential to reduce carbon footprints.” But then it goes on to say: “Individual behavioural change is insufficient for climate change mitigation unless embedded in structural and cultural change.” I cannot adequately summarize years of research and scientific studies into one pessimistic newsletter, so I encourage you to read the Policymakers’ Summary for yourself. You’ll need to set aside some quiet time to process it all, and maybe some kind of medication.
The WHO says 99% of us earthlings are breathing unsafe, polluted air. I guess the other 1% are living in the Congo rainforest or rural Russia. Oh, and average U.S. life expectancy dropped unsurprisingly, for the second year in a row—to 76.6 years; researchers mostly blamed white men and COVID for the dip.
I’m not certain how bad COVID has gotten in Shanghai, but supposedly it’s getting pretty bad. China is still aiming for a Zero-COVID policy, but the once-stalwart anti-COVID nations, like New Zealand, have given up to the dismay and plaudits of certain factions. Even Taiwan, which kept a fierce travel ban, testing regime, and pandemic discipline in place for almost the entire pandemic (so far), is dropping its Zero Covid strategy. (At least Taiwan still has a strategy, which can’t be said for most of the world.)
In more COVID news, Germany continues to break records for new cases. The UK is dealing with its highest infection rates since the start of the pandemic; in late March, about 1 in 13 people had COVID! Various officials close to U.S. President Biden (Nancy Pelosi, the Commerce Secretary, Joe Biden’s sister, and the Attorney General, among others) tested positive last week, and were near the double-boosted President; he has tested negative The second Pfizer booster is only good for about 8 weeks, an Israeli study says. This is your weekly reminder that Long-COVID is still dangerous and herd immunity is impossible. COVID raises your chances for cognitive problems, reproductive issues, heart maladies, and diabetes, among other risks—but I guess people just don’t care anymore. And pre-diabetes is on the rise across America and much of the indulgent world, where refined sugar is thought of as a core food group, and vegetable oil is practically considered a vegetable. Our food systems are at War with the population.
The Gulf Stream—which is the warm surface water of the AMOC—is responsible for carrying warm water from the Caribbean up to Iceland. This current has been weakening for ~200 years and is losing its strength faster than predicted. The implications of the end (a tipping point) of this uncertain oceanic current could be devastating, and, over the next few decades, we may be entering uncharted climatic waters, so to speak. Like many systemic ecological changes, there is no going back, and we Europe may be in deep trouble for a much colder future. Why do all tipping points seem to be converging in the same general time?
The melting ice sheets may also bring death to plankton in the ocean—so says the American defense tech company Northrop Grumman. This, along with illegal overfishing and ocean acidification, and microplastics, and more, could spell doom for our global fish stock, not to mention the hundreds of millions of jobs that depend on the ocean’s dwindling fisheries.
Pakistan’s embattled Prime Minister Imran Khan dissolved Parliament and called for new elections in a last-ditch attempt to remain in power, after an illegal political tactic was used to prevent the expected vote of No Confidence. Pakistan’s military, which helped him get elected in 2018, has supposedly lost faith in his ability to govern. Its economy, which wasn’t doing that great already, is worsened by the political situation, which could spiral out even further if tensions continue rising. Not far away, every cabinet minister in Sri Lanka resigned last week amid large protests against the newly instated curfew—which was instituted to clamp down on unrest resulting from long fuel lines, food shortages & price hikes, public debt, and a brewing energy crisis.
Birds in Panama are dying out and humans are to blame. Deforestation, changing climate patterns, and human development are eating away at their numbers. In Morocco, countless bees are dying as a result of prolonged drought and “colony collapse disorder.” Megadrought in the U.S. is leading to conflicts between counties that can’t agree on the urgent necessity to pipe water to needy localities.
Drought, a sinking economy, the Ukraine war, and fears for the future have led Uzbekistan into stockpiling grains and scared Kazakhstan into considering blocking grain exports. Poor nations from around the world are losing access to cheap grain since Russia and Ukraine’s Black Sea grain exports have been blocked, and global agricultural predictions for 2022 are quite low. Smart nations have stockpiled grain already, but in a weak harvest year where richer countries are stockpiling foodstuffs, won’t that make world hunger even worse than it is now? Nations of the world are playing musical chairs with global commodities, and countless people will be left standing when the music stops.
Some parties are taking advantage of the grain & oil pinch. Grain transporters in Argentina are demanding higher compensation for moving grain, since they know the economy is fake, inflation is real, oil is getting more expensive, and grain is getting harder to get. Investors see commodities like oil, coffee, grain, LNG, steel, lithium, soybeans, and more as a hedge against inflation. After all, you can’t eat cryptocurrency.
North Korea is facing a fuel shortage, too, alongside Kenya, Indonesia, and many other corners of the earth.
Lebanon is bankrupt, or so says the Deputy Prime Minister. The Central Bank of Lebanon denies this, of course. On Thursday, the IMF announced a plan to save Lebanon’s economy, with help from Saudi Arabia and other regional allies. The momentum of the small nation may already be irreversibly doomed to Collapse.
In some good news, solar & wind power, combined, now make up 10% of the world’s power generation. According to this Reuters summary of the IPCC report, “achieving net-zero carbon dioxide emissions in the 2050s…would require using about 95% less coal, 60% less oil, and 45% less gas by 2050.” Does anyone think that’s gonna happen?
A record April heatwave swept through Texas/Mexico on Wednesday, bringing 110 °F / 43.3 °C weather to the parched region. The dry season is looking to be so bad in Indonesia that they’re declaring a state of emergency before the dry season starts…
Deaths in Ethiopia’s Tigray War total half a million, including deaths by starvation and disease. Not far away, the 2014—present Yemeni Civil War (casualties: estimated 150,000) became more complicated when the exiled President ceded his powers to an 8-man (Saudi-orchestrated) “Presidential Council” selected by the six GCC countries. This complex political shakeup may enable Saudi Arabia and its anti-Iranian allies to prolong the War against the Iran-backed Houthi rebels in Yemen.
The Ukraine War has not progressed much from last week. Fewer than 2 months into the restarted conflict, over 11 million Ukrainians have been displaced from their homes. 27% of the population of the second-largest nation in Europe has left their homes; about 10% of the total population have left Ukraine altogether as refugees. The UN voted to remove Russia from the Human Rights Council, which won’t change the situation of the War one bit. The vote was 93-24; plus 58 abstentions. And, for some reason, it was quite hard to find any outlet that listed all the nations’ votes… Behind the scenes, there are more and more reports of degrading Russian morale, and that Finland is prepared to join NATO as soon as this year.
That Russian attack & occupation at Chernobyl is looking worse and worse every day in retrospect. Russian forces may be planning a renewed offensive in the eastern Donbas region, in what could be a shifting war goal for Vladimir Putin. Meanwhile, after Hungary’s Prime Minister Viktor Orban coasted to a fourth consecutive victory, the conservative EU country has no problems buying Russian gas using Russian rubles.
Russian soldiers have sunk to new lows, using Ukrainians as human shields, rape terrorism, torture, and brutal executions. Total deaths in the Ukraine War (since February 2022) are estimated at around 16,000 at the high end.
Things to watch next week include:
➳ Sunday, April 10: the first round of the French Presidential election, expected result in an April 24 rematch of Macron vs Le Pen. How will the lesser candidates fare?
➳ Ongoing protests in Sri Lanka, and the President who just won’t quit. How bad will it get?
➳ Fallout from the Pakistani Supreme Court ruling that the PM couldn’t’ve dissolved Parliament. Imran Khan also refuses to give up power. Is a constitutional crisis in the making, or a showdown between the government and the military?
➳ The potential collapse of the Israeli ruling coalition and a shift in power. The government is evenly split now; how might a new round of elections go? Will this impact the new Iran Deal?
➳ The weeks-long Shanghai lockdown is testing people’s patience, and their hunger. How will the people react as it drags on?
Select comments/threads from the subreddit last week suggest:
-Sri Lanka is fucked, according to this long & detailed post by someone living in Sri Lanka. It really helps bring into perspective the Collapse the island nation (pop: 22M) is facing.
-Your old life is over, the old world is over, according to this weekly observation in the subreddit. It’s just a question of who can notice accept the bizarre environmental/economic/psychological reality that is consuming us.
-Redditors shit on the popular YouTuber Kurzgesagt for his unbridled techno-optimism bordering on hopium propaganda. You be the judge.
-Existential dread is rising, according to this weekly observation from Germany. Also, prices of everything are skyrocketing. This observation from Wales, UK, says pretty much the same thing.
-A teenage collapsenik lays out his predictions for the most likely collapse scenarios, backed up with some good data. Most of the ideas are ecological in scope. It’s always refreshing to get predictions from the doompilled youth, as well as from the old people who have seen some real shit. Some of the comments in this thread are insightful, too.
One Last Thing: Over the past 15 weeks that I’ve been writing these, many readers of Last Week in Collapse have expressed a desire to receive this newsletter through email, instead of checking the subreddit every Saturday to find it. I am starting a SubStack version of this weekly roundup starting now, and you can sign up today to get next week’s edition of Last Week in Collapse sent right to your inbox (starting April 16). I’m starting the SubStack as an entirely free publication, but I will probably charge a nominal fee for this service at some time in the future. (I promise to continue to post a full edition to collapse , for free of course, as long as I continue writing Last Week in Collapse. I don’t believe anybody should be priced out of doom, or information.) The SubStack edition will be almost entirely identical to the Reddit version. (There is no spoiler text in Substack, but images can be embedded into the reports, etc etc, so there are small differences.)
Did you like this Collapse Report? Do you have any feedback, recommendations, questions, comments, articles, complaints, hate mail, farming advice, resources, writing critiques, news, shopping tips, horse maintenance guides, etc.? I publish a post like this every Saturday, and this was the longest edition yet. What did I miss?
submitted by LastWeekInCollapse to collapse [link] [comments]

The NOCEBO Effect

PRELUDE (Skip this is you want to): We all have our reason for loving the Stock, and all of us do it on our own. I've been in it since the January Sneeze, 2021... I have photos and screenshots of being locked out of my trading account and being placed on hold for 3 hours while monitoring RH (my secondary account at the time) as well as all the photos flooding in on WallStreetBets as retail traders reported actual stocks being censored out of the "Free Market"... When we say that they took away the buy button; that means that they took away the tickers completely. You couldn't get to them at all, they wouldn't come up in any results, regardless of the APEX broker. They were, in all actuality, Disappeared…
I don't know why I was feeling impressed to look at stocks the week prior, I don't know why I had this sudden urge to be more active in it. It had to do with being locked in for so long and the need to invest myself into something else. But living in the pandemic, with all the extra "policies" that they went ahead and put everyone through--even after the science indicated that these mandates, masks, and mrna shots could be harmful to the people.
This, after years of our political "leaders" pitting us against each other with lie after lie after lie, and harmful policy after harmful policy that stripped the public of freedom, liberty, and justice to line their own pockets and cover their own asses.
You see, I came down with a serious case of broken back just before Trump went to Washington. I had been an actor for 15 years, so watching movies (when you can't fill the roles) was maddening... So I studied current events and our politicians at work. I read anything I could find on every outlet for years, cross referencing and double checking statements... Needless to say, by January 2021, I needed to a new subject... Then it happened, they showed me that it wasn't free--and they were responsible. They turned off the buy button.
I sold all my investments and sunk them into the BANG Gang. GME, NOK, AMC, and BB. Those were all edited out of reality. With every paycheck (I have a broken back, I never registered as disabled, I use my mind to work), I was sinking more and more into GME first and AMC second. It was a nice balance. AMC was lining up like GME and AMCApes picked up everything they know from the OGApes of GME, and they learned quickly. But GME was the first problem, and thus they've been the ever-elephant in the room--spoken or unspoken.
Disclaimer: These companies are leading the market at hiring people right out of college, I imagine it has to do with ramping up Gamma on the Manipulation Index, possibly benefiting longevity… Remember the likelihood of blackmail victims being prevalent while reading this, many innocent people are not the bad actors here… It’s more likely only at the top...
[The NOCEBO Effect]
"History doesn't repeat itself, but it often rhymes" --Mark Twain
Grasp for a moment that there are companies older than countries, and these companies very much mimic immunosuppression.. Immunosuppression is a reduction of the activation or efficacy of the immune system. A live threat presents itself, and these companies shut down vital parts of the organism in order to allow the danger to continue under the radar… Boston Consulting Group, via the parent—Boston Group, is one said company.
Through research, the Apes have pulled forward a multitude of examples where predatory companies have broken the law to bankrupt businesses into nonexistence for their own gain. Citadel and Bain Capital have been engaging in Bust out schemes for decades, for the profit not only themselves but Amazon as well. It wasn’t until Boston Consulting Group sued GameStop for $30,000,000 that they were connected to these aforementioned entities, to the Apes’ knowledge. Then everything started clicking into place. BCG was at the center of much of this activity… BCG has been involved in directly consulting SEARS, JCPenney, Neiman Marcus, Kohls, Whole Foods, Circuit City, Blockbuster, Victoria’s Secret, ToysRus, KBToys [thank you for the display, u/BasicAd4976] And we’ve now uncovered connections to Blackberry, [AMC], Nokia, and GameStop. That’s the BANG-gang, Bangerang for the BANG-gang… BCG has placed consultants in these companies to advise how they move forward, they did this while Amazon (i.e. other clients) was targeting the industry of each of these and Citadel/Bain would short their company stocks... Bust Out Scheme. Looking at the dates of these activities, it becomes clearer with the more you look at them, they all acted these out at roughly the same time. This information is backed up by the amount that both Citadel and BCG trade players. [List from Anonymous]
But it doesn’t stop there, the deeper Apes Dig, the more they find on this particular pile of shit… u/THC_Is_Me did a remarkable DD on BCG’s connection with certain entities within the US Government.
https://www.reddit.com/Superstonk/comments/tz2ewg/bcg_is_a_terrorist_organization_disguised_as/?utm_medium=android_app&utm_source=share
I bet these Shitheads didn’t expect this…
Nocebo Effect: When the bad effects of trying to “fix” the situation ends up being worse than the bad situation that you’re in.
To the Reader: Please get ready for the worst theory rounded out, the type of thing you push back as paranoia… In this section, we round out how Boston Consulting Group (BCG) is a central part of a Global Collaboration that is locking Apes up and drugging them… Here we go…
June 2008: As of 2008, AstraZeneca hired Boston Consulting Group to help them penetrate the Chinese medical market. A Pfizer spokesman said the company doesn’t generally discuss marketing strategy, but said “we are currently experiencing reasonable growth in our prescription-drug business in China.” AstraZeneca’s push into China began in earnest around 2002. Bruno Angelici, its executive VP for International sales and marketing outside of the US and Canada, started traveling to China regularly. The Company hired BCG in Hong Kong, where Mr. Yin worked at the time, to draw up a plan for the Chinese market. AstraZeneca’s sales in China had been growing at around 12% annually, but Mr. Angelici wanted more. Though he had commitment for more funding from AstraZeneca’s London headquarters, the problem was where to spend it; the country’s eastern cities were saturated with sales representatives, so AstraZeneca looked inland. Mr. Yin had a list of nearly 700 cities, with data on each ranging from per capita spending on health care to population projections. They narrowed the list down to around 200 of the most promising cities and nicknamed the strategy Project 88. Mr. Yin and his team at Boston Consulting developed a computer algorithm to help decide where to put sales representatives. Mr. Yin says the algorithm told them to bulk up significantly in Xinjiang… In 2002, AstraZeneca had around 8 sales reps in Xingjiang, by 2008, it had 43. “Now, everybody is interested in Xinjiang”, stated Mr. Yin of Boston Consulting Group at the time… Uighur, the Turkic language, is widely used in this province (twice the size of Texas). https://www.wsj.com/articles/SB121331518414669979
July 2009: Urumqi riots ostensibly started as a peaceful street protest demanding official action over two Uyghurs who died in Shaogun. After 70 of their leaders were taken into custody, a group of 1000 people were gathered in front of the hospital in Shanxi Alley, the biggest of the crowds that were protesting in the province. The matter was blamed on racism. Many Uyghurs were disappeared and according to China News Service, by 2010, at least 26 Uyghurs had received death sentances. Following trials in October of 2009, one person was executed and several others were sentenced to between 5 to 7 years and life imprisonment… https://en.m.wikipedia.org/wki/July_2009_%C3%9Cr%C3%BCmqi_riots
So BCG begins working with AstraZeneca in 2008, targeting Xinjiang Provence in China, and by 2009 they are rioting outside of hospitals… The media blamed it on Racism…
Since then, Chinese government reports that birth rates in mostly Uyghur regions of Hotan and Kashgar fell by more than 60%. In the same period, the birth rate of the whole country only decreased by 9.69%... Authorities admit that birth rates dropped by almost 1/3 in Xinjiang in 2018, but denied reports of “forced sterilization and genocide”. Birth rates fell a further 24% in 2019, compared to 4.2% nationwide… https://en.m.wikipedia.org/wik/Uyghur_genocide
Pretty sure we’ve all heard the phrase “Uyghur Genocide”. The question is, why? Moving on…
2014-15 Sierra Leone: "San Francisco-based Metabiota Inc. was tapped by the Sierra Leonean government and the World Health Organization to help monitor the spread of the virus and support the response after Ebola was discovered circulating in neighboring Guinea in March 2014. But emails obtained by AP and interviews with aid workers on the ground show that some of the company's actions made an already chaotic situation worse. "Metabiota's team worked tirelessly, skillfully and at substantial potential danger to themselves to assist when most of the world was still ignoring the problem," he said in an email. "We are proud of our team efforts which went above and beyond the call of duty." Wolfe said some of the problems flagged were misunderstandings - and that others were planted by commercial rivals... "We didn't have the personnel and the infrastructure that was needed to handle the onslaught of cases that were coming," he said. "We were doing the best we had with what we had there." -- Dr. Bob Garry https://www.cbsnews.com/news/american-company-metabiota-problems-during-ebola-outbreak/
"The United Nations called on BCG to help manage the worldwide response to the fast-moving Ebola crisis. Within 48 hours, BCG had a team in place at U.N. headquarters in New York. Working closely with the World Health Organization (WHO), BCG supported the initial design of the Ebola response and developed a novel 30-60-90 day plan to get the epidemic under control. After the initial planning, the United Nations Mission for Ebola Emergency Response (UNMEER) deployed to West Africa, and so did BCG. Shortly thereafter, BCG helped design and facilitate a pivotal four-day planning conference in Accra, Ghana, that brought more than 80 experts together with all the major partners to align on a robust, unified response strategy and implementation plan for the three affected countries—Guinea, Sierra Leone, and Liberia. U.N. officials later cited the meeting as a turning point in the Ebola fight. In all, BCG invested $2.2 million in professional fees and expenses in the Ebola effort. BCG’s analysis found that for too long, the response to the outbreak was “virus centric,” focused on getting resources and technical solutions in place. It was only when the response also became “people focused”—understanding and adapting to the influences of culture, beliefs, and practices—that Ebola began to be brought under control and communities became more likely to accept the response." https://www.bcg.com/capabilities/social-impact-sustainability/smarter-ways-fight-ebola
Oct. 2014: Air Worldwide out of Boston [A Verisk Analytics, NJ company (Weather Catastrophe consulting company for the insurance industry as of 2003] stated at the time, “There is a high level of uncertainty associated with estimating the dynamics of a disease during an on-going outbreak. Preliminary estimates from AIR's soon-to-be-released Emerging Infectious Disease Model (which will be part of the updated AIR Pandemic Model) suggest that the projected outbreak sizes reported by these various groups are possible, especially if mitigation and containment measures in West Africa are not expanded. While containing the current outbreak has proven difficult, the risk of sustained and widespread infection across multiple continents remains low. Scientists have used simulations of travel by airplane and local disease transmission dynamics to estimate the probability that an individual infected with Ebola will enter a foreign country undetected, and the expected number of people who would subsequently be infected.” Take a look at what their pandemic model covers in the Editor’s Note… Editor's Note: The forthcoming update to AIR's pandemic model will cover emerging infectious diseases, including coronaviruses and filoviruses such as Marburg and Ebola. The Ebola outbreak is currently showing no signs of slowing, and projections show the possibility that hundreds of thousands of people could be infected by early next year, mainly in West Africa. The potential for sustained and widespread infection across multiple continents remains low. AIR disease modeling experts share their insights in this article. https://www.air-worldwide.com/publications/air-currents/2014/Understanding-the-Ebola-Outbreak/
Aug. 2015: The Global Health Risk Framework Project Workshop on Pandemic Financing found Metabiota CEO Wolfe on a panel with AirWorldwide Principle Scientist Nita Madhav (now Metabiota CEO and World Economic Forum Jr. member) discussing the Identification of Triggers and Modeling Risk, while BCG moderated directly afterword on the same, as well as on a panel discussing Investment Case for Preparedness and the Role of the Private Sector. https://nap.nationalacademies.org/read/21855/chapte13#83
Apr. 2016: AIRWorldwide Pandemic Model: Event ID 810254128 This Megadisaster scenario, with Event ID 810254128 in the stochastic catalog of the AIR Pandemic Model, kills nearly 23 million people and sickens more than 2.6 billion. In the early stages of the event, particularly in resource-limited regions, reporting agencies are overwhelmed by the magnitude of cases and deaths. Illness severity ranges from mild flu-like symptoms (i.e., fever, chills, malaise, cough, etc.) for which those infected may not seek treatment, to critical outcomes involving coinfections (such as pneumococcal pneumonia) that mandate hospitalization in an intensive care unit (ICU) or cause death. This modeled event causes about 300,000 deaths, 4 million hospitalizations, and 40 million outpatient clinic appointments in the United States alone. https://www.air-worldwide.com/publications/air-currents/2016/global-pandemic-megadisaster-are-you-prepared/
2017: Metabiota partners with Amazon's AWS rescale to tackle big epidemics (Pandemics) https://aws.amazon.com/partners/success/metabiota-rescale/ https://rescale.com/big-epidemics-big-cloud-computing/
Feb. 2019: Merck acquires Antelliq for their bovine tracking system and the potential therein, "Merck was represented by Barclays and Centerview Partners and Antelliq was represented by Goldman Sachs International, BCG and Rothschild & Co... BCG did the VDD (Vendor Due Diligence) for BC Partners and Antelliq. We knew the asset from the previous transaction in 2013 and we were amazed by the digital transformation achieved in five years. The company went from a leader in traditional livestock identification tags (e.g. the plastic tags in cows’ ears), to a fully-fledged data management company. This was enabled by the acquisition of an Israeli startup, and the development deployment of a “big data” smart monitoring system." https://www.finance-monthly.com/2019/02/merck-to-acquire-antelliq-group/
An application garnering increased interest is the use of real-world evidence to serve as synthetic control arms (SCAs), dramatically changing the historical approach to clinical development testing. SCAs have the potential to reduce the number of patients required in traditional control arms, especially active-comparator or standard-of-care arms, thereby decreasing the study cost, accelerating the speed to result, and boosting the overall attractiveness of clinical trial participation for prospective patients.
Indeed, all signs indicate that the use of SCAs is poised to take off. The relevant data is becoming more readily available, and the advanced analytics needed to gain insights are rapidly improving. Moreover, regulators have become increasingly open to accepting the results of SCAs as the basis for decisions and are supporting efforts to test their use. Adding to these catalysts, the COVID-19 pandemic is expected to accelerate efforts to expand the use of real-world evidence in the pharma industry." https://www.bcg.com/publications/2021/synthetic-control-arms-changing-clinical-trials
October 2019: This article breaks down the BCG Classic/Platinion/Digital Ventures/Gamma divisions: BCG "Classic" focuses on analyzing a business problem or scenario and making a recommendation. Platinion is actually building and implementing technology - this is the "enablement" part. DV is focused on growth beyond the core business through digital means (digitalizing). BCG Gamma is focused on data science technology: it's building algorithms, machine learning systems and other data intensive products for its clients (might include mining all their existing customer data, marrying it with publicly available customer information and building a prediction engine to determine which customers are likely to become valuable in the future.) Ultimately, BCG is pursuing a strategy that allows it to help its clients run the gamut: from helping define right strategy to building the right technology to follow through on it. In many ways, BCG has already proven that the hypothesis of strategy plus implementation works. For example, BCG has a well regarded post-merger integration practice which is focused on how to successfully integrate an acquired company, not on the strategic decision itself to acquire (or not acquire) a company. [See also Bain Vector and McKinsey Digital] https://www.rocketblocks.me/blog/bcg-platinion-overview.php
Next we consider a very special vaccine called Bacillus Calmette–Guérin (BCG, I shit you not)... Serious side effects are rare. Often, redness, swelling, and mild pain occur at the site of injection. A small ulcer may also form with some scarring after healing. Side effects are more common and potentially more severe in those with immunosuppression. The BCG vaccine was first used medically in 1921, so it's nice and cheap. It is on the World Health Organization's List of Essential Medicines. As of 2004, the vaccine is given to about 100 million children per year globally... It is encouraged in areas that where leprosy and tuberculosis are more common, is applied to fighting cancer, it has been one of the most useful immunotherapies to date, has been the standard against bladder cancer for some time, and was originally developed from Mycobacterium bovis, which is commonly found in cattle...
Approximately, 1.5 million people died from TB in 2020 (including 214,000 among HIV positive people). WHO modelling projections suggest the number of people developing TB and dying from the disease could be much higher in 2021 and 2022.
I know, it’s getting dark quickly… I’m going to give a side fact to give you a moment…
Side fact: One of the main scientists that brought BCG about was Albert Calmette. He also came up with the Amylolytic process or amylolysis is the conversion of starch into sugar by the action of acids or enzymes such as amylase... Brewing/distilling. The amylolytic process is also useful in the breaking down of molecules, it can be closely associated with the process of hydrolysis (molecular breakdown with water)... He also pioneered antivenom. https://en.m.wikipedia.org/wiki/Albert_Calmette
"Talk is cheap, it takes money to buy whiskey." --RC
Steroids were the first class of immunosuppressant drugs identified, though side-effects of early compounds limited their use. The more specific [vague] azathioprine was identified in 1960, but it was the discovery of ciclosporin in 1980 (together with azathioprine) that allowed significant expansion of transplantation to less well-matched donor-recipient pairs as well as broad application to lung transplantation, pancreas transplantation, and heart transplantation. After an organ transplantation, the body will nearly always reject the new organ(s) due to differences in human leukocyte antigen between the donor and recipient. As a result, the immune system detects the new tissue as "foreign", and attempts to remove it by attacking it with white blood cells, resulting in the death of the donated tissue. Immunosuppressants are administered in order to help prevent rejection; however, the body becomes more vulnerable to infections and malignancy during the course of such treatment. https://en.m.wikipedia.org/wiki/Immunosuppression
"eew eew llams a evah I" --RC
An example of non-deliberately induced immunosuppression is HIV... It’s still rather dark, I’m sorry…
I know what you’re thinking, what does this have to do with the equasion?? Well, Merck & Co is the sole distributor of BCG vaccine, and they're consulted by... You guessed it, BCG... Along with Moderna, and Astrazenica respectively. Pfizer and Johnson&Johnson are represented by McKinsey (McKinsey advised J&J to increase Opioid sales when epidemic was widespread according to July 2019 article from NYTimes). And in—
2019: Merck "began having shortages" in their production of BCG vaccines... Do you recall reports of cancer patients dying because they aren't going in to get treated? 100 million children a year... It makes you wonder at why the sudden drop in production... Last year, Merck & Co., the only maker and supplier of BCG to the United States, informed the AUA they were experiencing a global shortage of BCG due the growing use and need for this product around the world. For more than a year, the AUA has been actively monitoring the global shortage of bacillus Calmette Guerin (BCG), and providing updates to members about this important concern. https://www.auanet.org/about-us/bcg-shortage-info
2020: "Since 2012, Merck has been the only manufacturer of BCG for patients in the U.S. and European markets... Although Merck’s new North Carolina facility will take around five to six years to build, it is expected to eventually triple their capacity" ...Are you kidding me, 5 to 6 years??
Apr. 1, 2020: Boston Consulting Group has been awarded a 6-month contract with the Centers for Medicare and Medicaid Services for a Mission Essential Function Risk Based Scenario Planning Exercise. This contract is awarded in support of the OA Organizational Efficiency Assessment initiative. The contract was awarded using the GSA Professional Services Schedule (PSS). CMS awards Contract for Mission Essential Function Risk Based Scenario Planning Exercise - FedHealthIT, a service of MileMarker10
Apr. 2020: "BCGDV portfolio company LabTwin is helping researchers fight the COVID-19 pandemic... the National Institute of Allergy and Infectious Diseases (NIAID) is collaborating with Moderna on their mRNA vaccine against the novel coronavirus... AI and machine learning tools can also help diagnose patients with COVID-19, and predict the spread of the virus... Companies such as Canada’s BlueDot and Metabiota in the US use AI to predict disease outbreaks from news and health-care reports." https://medium.com/bcg-digital-ventures/how-ai-and-digital-lab-tools-are-joining-the-fight-against-covid-19-b759ff08b309
August 2020: The Centers for Medicare and Medicaid Services (CMS) intends to negotiate and award a sole source purchase order to The Boston Consulting Group, Inc, 4800 Hampden Lane, Bethesda, MD 20814-2938 (It was interesting that there were so many sole sourse awards). The sole source award will be made under the authority of 41 U.S.C. 235 (C) (1) as implemented by FAR6.302-1, Only One Responsible Source and No Other Supplies and Services Will Satisfy Agency Requirements. A justification and approval is currently being processed for this requirement. CMS REQUIREMENTS: Boston Consulting Group (BCG) provides development, planning, and execution of risk-based scenario planning and response to assess and mitigate CMS’s potential program and operational risks associated with performing mission essential functions while responding to the COVID-19 pandemic. BCG delivers comprehensive analysis and support to CMS for pandemic response and risk management efforts. Boston Consulting Group will provide the following consulting services CMS: • Analysis of Potential Events that will impact CMS’s Operations and Programmatic Activities • Development and Management of a “Response Cycle” to Pandemic-related External Events • Sustainment of Ongoing Pandemic Response Initiatives • Enablement through Evolution of CMS’s Operating Models and Organization CMS to award Execution of risk-based scenario planning and response task - COVID-19 - FedHealthIT, a service of MileMarker10
Oct. 2020: The purpose of the logical follow-on contract is to provide the Centers for Medicare & Medicaid Services (CMS) with support to develop, plan, and perform risk-based scenario planning and response exercises that assess and mitigate potential program and operational risks associated with performing mission essential functions while responding to the COVID-19 pandemic. The current task order, GS-10F-0253V/75FCMC20F0029, was awarded as a sole source award in accordance with FAR 8.405-6 Urgent & Compelling and has a period of performance of March 24, 2020 through September 23, 2020. The contract will support CMS/OA to identify, define and prioritize scenarios with the COVID-19 workgroup. These scenarios will focus on the potential for negative risks associated with vulnerabilities or weaknesses that may arise while trying to execute on mission essential functions while responding to the COVID-19 pandemic. In addition, the contractor will support prioritization of outcomes, mitigation planning and execution, and organizing responses from stakeholders. The unprecedented nature of this COVID-19 pandemic and the potential further disruption necessitate an agency-wide response effort to update and execute existing response mechanisms, and to design new interventions to meet these challenges. Boston Consulting Group (BCG) is uniquely positioned to begin this urgent work immediately. BCG has extensive experience at CMS supporting strategic initiatives within the Office of the Administrator over the last year and a half. Most recently, within the past six months BCG has stood up the initial pandemic response and risk management efforts and worked with CMS in the evolution of the public health emergency in order to deploy support against the most critical needs of the agency. Over this time BCG has gained a thorough understanding of CMS strategic priorities, operations and has successfully delivered complex services within CMS’ portfolio of work and response to the COVID-19 pandemic. As this contract is in response to the COVID-19 pandemic we do not anticipate future requirements, but if a similar requirement arises, every effort will be made to compete it to the maximum extent possible. CMS awards contract for Execution of risk-based scenario planning and response to COVID-19 - FedHealthIT, a service of MileMarker10 Mar. 2021: https://mobile.twitter.com/bcg/status/1372960309254705155
April 2021: The Boston Consulting Group (BCG) has been awarded a 6-month task by the National Institutes of Health for CDC program management and strategic analysis support for vaccine distribution and administration. This task, valued at $5M, was awarded using the HHS COVID-19 Support BPA. https://www.fedhealthit.com/2021/04/nih-awards-5m-cdc-program-management-and-strategic-analysis-support-task/
May 2021: https://mobile.twitter.com/BCG/status/1389248020601098240
June 2021: An unnamed consulting company, which Vox has identified as BCG, charged the World Health Organization $11.72 million since the start of the pandemic for contracts that were dubiously awarded, according to the audit. Before the pandemic, Vox revealed the WHO committed at least $12 million on consultants to support the agency’s reform, approximately a quarter of which has been paid for directly by the Bill and Melinda Gates Foundation. At the time, a WHO spokesperson said the agency welcomed consultants’ work. “The [consulting] companies have supported WHO in areas where we lack in-house expertise or want to tap the current best-in-class standards.” The audit, which examines a sampling of the WHO’s biggest contracts, analyzed the agency’s work with BCG, known as “Consulting Firm A” in the report, and uncovered multiple violations of WHO policies. The auditors claim WHO staff sought to circumvent the organization’s public procurement rules in order to help BCG win a contract. https://www.vox.com/2021/6/16/22527665/world-health-organization-who-12-million-bcg-consultants See Also: McKinsey infiltrated the world of global public health. Here’s how. - Vox
June 2021: Metabiota is named a Pioneer in the World Economic Forum https://www.pilotgrowth.com/metabiota-awarded-as-technology-pioneer-by-world-economic-forum/
July 2021: Moderna sits down with Sam Ransbotham and Shervin Khodabandeh, senior partner with BCG, colead to BCG’s AI practice in North America. Together, MIT SMR and BCG have been researching AI for five years, interviewing hundreds of practitioners and surveying thousands of companies on what it takes to build and to deploy and scale AI capabilities across the organization and really transform the way organizations operate. .... Sam Ransbotham: Take us back to early in the COVID race for a vaccine. What was it like being part of that team and a part of that process? I mean, what were the emotions like when the algorithms … or when the people find something that seems to work or that seems promising? Does that lead to a massive appetite for more artificial intelligence and more algorithms? Tell us a little bit about that story.
Dave Johnson: I think if you look at how people felt in general at the time, it was a real sense of honor and pride. We felt very uniquely positioned. We’d spent a decade getting to this point and putting all of this infrastructure in place and putting things in the clinic before this to get to this moment. And so we just really felt truly honored to be in that position. And for those of us on the digital side who have kind of contributed to this and built it, this is why we did it. This is why we’re here: to help bring as many patients [these vaccines] as quickly and safely as possible [throughout] the world. But there was always the question of, “Would this thing work in the real world?” And that’s where the proof came in the clinical data, and we were all anxiously waiting — like everybody else — to see that readout." https://sloanreview.mit.edu/audio/ai-and-the-covid-19-vaccine-modernas-dave-johnson/
Notice the way Shervin Khodabandeh tried to stear the conversation, if you care to read it. Moderna highlights that they were working on this for a decade to be able to push experimental drugs flawlessly…
August 2021: California wasn’t alone in using private contractors (McKinsey) to manage the vaccination campaign. At least 25 states, along with federal agencies and many cities and counties, hired consulting firms, according to a Washington Post tally. The American vaccination drive came to rely on global behemoths such as McKinsey and Boston Consulting Group (BCG), with downsized state and local health departments and even federal health agencies relying on the private sector to make vaccines available to their citizens, according to hundreds of pages of contract documents, emails and text messages obtained through public records requests. McKinsey’s role extended beyond California to other states, including Ohio and New Jersey. Deloitte worked in 10 states. BCG received millions of dollars from the federal government to coordinate vaccine planning, while at least 11 states also worked with the company, in some cases paying it to address gaps in federal planning. https://www.washingtonpost.com/health/2021/08/22/private-consultants-vaccination-drive-outsourced/
August 2021: Pharmaceutical giant Pfizer has hired Aamir Malik, a senior partner in McKinsey & Company’s pharma & medical products practice, as EVP and chief business innovation officer. Malik succeeds John Young, who held the role for the last three years. Young will retire in 2022, having spent 34 years at Pfizer. As dealmaking leader, Young oversaw the company’s Covid-19 vaccine collaboration with BioNTech. https://www.consulting.us/news/6493/pfizer-hires-mckinseys-aamir-malik-as-dealmaking-chief
But wait, there’s still a missing piece to all this. That one aspect that was mentioned that seemingly cut short of it’s conclusion… And here it is in the Time-line… Apparently Bacillus Calmette-Guérin, the Merck vaccine, is effective against COVID—yes, seriously... As it’s the reverse of an immunosuppresent, it offers mechanisms involved in immunological protections against viral infections such as Covid, and has a deeper connection than has been covered by the Media--that has been in an all-out Wall Street propaganda campaign against Apes since the beginning!!
Nov. 2021: Cedars-Sinai "It appears that BCG-vaccinated individuals either may have been less sick or they may have mounted a more efficient cellular immune response against the virus," says Moshe Arditi, MD, executive vice chair for Research in the Department of Pediatrics, director of the Division of Pediatric Infectious Diseases, and the GUESS?/Fashion Industries Guild Chair in Community Child Health. https://www.cedars-sinai.org/discoveries/tb-vaccines-and-covid-19.html
Dec. 2021: Boston Consulting Group says, "The emergence of the Omicron variant has elevated the importance of vaccination and vaccine mandates in the fight against COVID-19. While uncertainties and legal challenges remain, by early 2022 most companies in the US with more than 100 employees will likely be operating under a vaccination or testing mandate to contain the spread of COVID-19. Even with the emergence of a new “variant of concern,” mandates remain a divisive issue but not an unsolvable one... The Biden administration’s overarching goal is to increase vaccination rates. The three policies are powerful, complex, and interlocked tools: Biden’s executive order covers federal contractors; another (under OSHA’s emergency temporary standard) applies to all organizations with at least 100 employees. And a third (imposed by the US Department of Health’s Centers for Medicare and Medicaid Services) covers staff at organizations receiving Medicaid or Medicare funds." https://www.bcg.com/publications/2021/covid-19-us-vaccine-sentiment-series
2022: "Evidence from multiple scientific studies suggests that the Bacillus Calmette-Guérin (BCG) vaccine, widely used worldwide as a preventive measure against tuberculosis, also offers cross-protection against other pathogens. This review aimed to gather data from research that studied the mechanisms involved in the immunological protection induced by the BCG vaccine, which may be important in the control of viral infections, such as COVID-19." https://pubmed.ncbi.nlm.nih.gov/34983348/
These same that entered into Xinjiang before the birth rates plummeted astronomically; these same that were in West Africa during the Ebola Outbreak; these same that have been helping to bankrupt our businesses and costing 100s of thousands of jobs; these same that were involved in the crash of 2008... These are the ones behind the global lockdowns and mandates of “Science”, we’re just shown Anthony Fauci… DOJ… Can't dumb it down further than that because I worked on this possible DD alone; Do your jobs…
“Children & Animals must be protected at all costs”—RC
Date unkown*: https://www.disabledperson.com/jobs/15732217-cdc-coordinator
(This is by no means medical or financial advice.)
submitted by Roolery to DeepFuckingValue [link] [comments]

مؤشر خليك في بيتك ومسابقة 10 دولار

خيارات الخيارات الثنائية 60 seconds binary options free demo account. شركة binary betting system فوريكس الفوركس فى مصر خيارات للتجارة هي ذات الخطورة العالية ويمكن أن يؤدي إلى فقدان جزئي أو الخيارات الثنائية. موقع تداول. اخبار مصر العاجلة اخبارك نت ... اكتشاف الحقيقة وراء قضية Cedar Finance احتيال. قراءة المزيد حول كيفية تحدد الخيارات الثنائية لا يمكن الاعتماد عليها وسيط ما يجعل Cedar Finance يست عملية احتيال. الخيارات الثنائية احتيال. سوق الخيارات الثنائية. إشارة الخيارات الثنائية. الخيارات الثنائية بوت. كيفية تداول الفوركس. كيفية تداول الخيارات الثنائية. نظام الخيارات الثنائية. طريقة الخيارات الثنائية. 24option ، stockpair ، grandopt تداول الخيارات الثنائية مع مكافأة خاصة! التسجيل في Cedar Finance الفوركس قائمة الخيارات الثنائية قائمة الوسطاء الثنائيين. أحدث وسطاء الفوركس. يحمل تداول الفوركس مستوى عاليًا من المخاطر وقد لا يكون مناسبًا لجميع المستثمرين. قبل الانخراط في تداول العملات الأجنبية ، يرجى التعرف على ...

[index] [9494] [7894] [5955] [6591] [11881] [11318] [5572] [10169] [4515] [4247]

مؤشر خليك في بيتك ومسابقة 10 دولار

الخيارات الثنائية حلال ام حرام الخيارات الثنائية بدون ايداع الخيارات الثنائية المتداول العربي شركات ...

#

test2